Participants achieving HBsAg loss with pegylated interferon alfa (PEG-IFNα) ± elebsiran or BRII-179 demonstrated favorable off-treatment clinical outcomes, with most HBsAg rebounds ‑treatment ...
Please provide your email address to receive an email when new articles are posted on . Higher end-of-treatment hepatitis B surface antigen level correlated with nucleos(t)ide clinical relapse among ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Up to 19% of patients who received JNJ-3989 achieved ...
(RTTNews) - Vir Biotechnology Inc. (VIR) announced new data from its ongoing Phase 2 clinical trials of VIR-2218 and ongoing Phase 1 studies of VIR-3434 in patients with chronic hepatitis B virus or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results